Literature DB >> 30728710

The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region.

Yasemin Benderli Cihan1.   

Abstract

Entities:  

Year:  2018        PMID： 30728710      PMCID： PMC6328827          DOI： 10.1007/s12663-018-1138-8

Source DB:  PubMed          Journal:  J Maxillofac Oral Surg        ISSN： 0972-8270


× No keyword cloud information.
  7 in total

1.  Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Authors:  R L Ferris; J L Geiger; S Trivedi; N C Schmitt; D E Heron; J T Johnson; S Kim; U Duvvuri; D A Clump; J E Bauman; J P Ohr; W E Gooding; A Argiris
Journal:  Ann Oncol       Date:  2016-10-11       Impact factor: 32.976

2.  Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

Authors:  Ricard Mesía; Michael Henke; Andre Fortin; Heikki Minn; Alejandro Cesar Yunes Ancona; Anthony Cmelak; Avi B Markowitz; Sebastien J Hotte; Simron Singh; Anthony T C Chan; Marco C Merlano; Krzysztof Skladowski; Alicia Zhang; Kelly S Oliner; Ari VanderWalde; Jordi Giralt
Journal:  Lancet Oncol       Date:  2015-01-15       Impact factor: 41.316

3.  Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

Authors:  Jordi Giralt; Jose Trigo; Sandra Nuyts; Mahmut Ozsahin; Krzysztof Skladowski; Georges Hatoum; Jean-Francois Daisne; Alejandro César Yunes Ancona; Anthony Cmelak; Ricard Mesía; Alicia Zhang; Kelly S Oliner; Ari VanderWalde
Journal:  Lancet Oncol       Date:  2015-01-15       Impact factor: 41.316

4.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.

Authors:  Lillian L Siu; John N Waldron; Bingshu E Chen; Eric Winquist; Jim R Wright; Abdenour Nabid; John H Hay; Jolie Ringash; Geoffrey Liu; Ana Johnson; George Shenouda; Martin Chasen; Andrew Pearce; James B Butler; Stephen Breen; Eric Xueyu Chen; T J FitzGerald; T J Childs; Alexander Montenegro; Brian O'Sullivan; Wendy R Parulekar
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

Review 5.  Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.

Authors:  Alex Françoso; Patricia Ucelli Simioni
Journal:  Drug Des Devel Ther       Date:  2017-01-11       Impact factor: 4.162

6.  Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.

Authors:  Bella Pajares; Jose M Trigo; Maria D Toledo; Martina Álvarez; Carlos González-Hermoso; Antonio Rueda; Jose A Medina; Vanessa de Luque; Jose M Jerez; Emilio Alba
Journal:  BMC Cancer       Date:  2013-01-18       Impact factor: 4.430

Review 7.  Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Authors:  Shiven B Patel; David Gill; Ignacio Garrido-Laguna
Journal:  Onco Targets Ther       Date:  2015-12-30       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.